1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
SHARMA A, OFSTAD A, AHMAD T, ZINMAN B, ZWIENER I, FITCHETT D, WANNER C, GEORGE J, HANTEL S, DESAI N, MENTZ R. 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1144-p.Peer-Reviewed Original ResearchCV deathNovartis Pharmaceuticals CorporationPhenotype of patientsTreatment effectsEli LillyEMPA-REG OUTCOMERisk of outcomesType 2 diabetesAdvisory PanelBoehringer Ingelheim PharmaceuticalsBristol-Myers SquibbEMPA-REGMundipharma InternationalSanofi GenzymeCardiovascular deathCV diseaseT2D durationOlder patientsYounger patientsHeart failureAtherosclerotic diseaseSGLT2 inhibitionCox regressionDohme Corp.Patients